Virometix AG. (2/1/19). "Press Release: Virometix AG Appoints New CEO". Schlieren.

	Organisation	Virometix AG
	Organisation 2	Alacrita AG
	Product	immunotherapy
	Product 2	Synthetic Virus-Like Particle technology (SVLP technology)
	Person	Sumeray (formerly Casse), Anna (Virometix 201902– CEO before Alacrita + BioVault + Ariad Europe + Novartis + ADL)

Virometix today announced the appointment of Anna Sumeray as Chief Executive Officer.

Virometix, a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the appointment of Anna Sumeray as Chief Executive Officer. She succeeds Arin Ghasparian, who will remain member of the Board of Directors. The Board of Directors wishes to thank Mr Ghasparian for his valuable contribution to the development of the Company, as Chief Executive Officer during the last six years.

Anna Sumeray brings more than 25 years of business leadership in the pharmaceutical and biotechnology industries. Ms. Sumeray currently serves as Managing Partner of Alacrita, a global life science consulting firm where she is responsible for the European operations and Commercial Practice. Prior to this, she was responsible for building the European entity for ARIAD Pharmaceuticals from the ground up and achieved the successful launch of ponatinib in Europe across 17 countries.

Ms. Sumeray began her career in the life science industry at Amgen in business analysis and strategic planning, and moved to Novartis where she progressed through successive positions of increasing responsibility, including Head of Novartis Ophthalmics Global Business Development and Licensing and roles with P&L responsibility at Novartis Oncology in Finland, Novartis Oncology Germany and Nephrology and Transplantation at Sandoz.

She is also the owner of BioVault, an investment and consultancy company for start-up biotech companies and has been advising management of and making private investments in early-stage ventures for over 20 years.

A fluent speaker of several languages, Anna holds an MBA from INSEAD and a Bachelor of Sciences in biochemistry from the University of Birmingham.

Pierre Morgon, Chairman of the Board of Directors of Virometix commented: “We are delighted to welcome Anna as Chief Executive Officer of Virometix. Her 25 years’ of diverse experience across diverse types of organizations and her track record of developing international businesses will be key advantages for the expansion of Virometix.”

Anna Sumeray, incoming Chief Executive Officer of Virometix, added, “I am joining the Virometix team with great enthusiasm and look forward to contributing my skills and experience to the advancement of the Virometix development activities and international partnering.”

For further details please contact:

Dr. Pierre Morgon
pierre.morgon@virometix.com
www.virometix.com

About Virometix AG

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and cancer. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.

For more information about Virometix AG please visit: http://www.virometix.com/

Record changed: 2023-06-05